Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Highlights this week included:

US: Unanimous Supreme Court finds personalized medicine claims not patentable: Mayo v. Prometheus (Kluwer Patent Blog) (Orange Book Blog) (Patently-O) (Inventive Step) (Pharma Patents) (Pharma Patents) (Patent Docs) (Patent Docs) (Patent Docs) (Holman’s Biotech IP Blog) (PatLit) (IP Spotlight) (IP Watch) (Maier & Maier) (EFF) (KEI) (Spicy IP) (Ars Technica) (Patent Docs) (IPKat) (BIOtechNOW) (Patently-O) (Patently-O)

US: Supreme Court sends Myriad back to the Federal Circuit (Pharma Patents) (Patent Docs) (Holman’s Biotech IP Blog) (Patently-O) (IP Watch) (Ars Technica)

Kaletra (Ritonavir and Lopinavir) – Brazil HIV drug patent ruling allows generics, sends pipeline process into doubt (IP Watch)

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

General

Incentivising diseases? (Spicy IP)

Global Fund changes continue as West Africa team leader departs (IP Watch)

New book on the way – “Application and Importance of Supplementary Protection Certificates in the European Union” (The SPC Blog)

EU: ZYDUS and ZIMBUS slug it out in General Court: Cadila Healthcare v OHIM and Novartis (IPKat)

Israel: Mistakes by staff of Israel’s largest patent firm considered unavoidable: Application for Patent Term Extension for 154325 by Centocor Ortho Biotech Inc (The IP Factor) (The SPC Blog)

UK: GSK confirms £500m manufacturing investment is due to patent tax break (Out-Law)

US: Unanimous Supreme Court finds personalized medicine claims not patentable: Mayo v. Prometheus (Kluwer Patent Blog) (Orange Book Blog) (Patently-O) (Inventive Step) (Pharma Patents) (Pharma Patents) (Patent Docs) (Patent Docs) (Patent Docs) (Holman’s Biotech IP Blog) (PatLit) (IP Spotlight) (IP Watch) (Maier & Maier) (EFF) (KEI) (Spicy IP) (Ars Technica) (Patent Docs) (IPKat) (BIOtechNOW) (Patently-O) (Patently-O)

US: Scholarship cited by the Supreme Court in Mayo v. Prometheus (Patently-O) (Patent Quality Matters)

US: Mayo v. Prometheus – What should we do? (or can these claims be saved?) (Patent Docs)

US: Examining subject matter eligibility under Mayo v. Prometheus – USPTO guidance for examiners  (Patently-O) (Inventive Step)

US: Supreme Court sends Myriad back to the Federal Circuit (Pharma Patents) (Patent Docs) (Holman’s Biotech IP Blog) (Patently-O) (IP Watch) (Ars Technica)

US: KEI comments to USPTO on genetic diagnostic testing (KEI)

US: You had us at “biosimilars,” FDA; agency ties up yet another biosimilars loose end with petition response concerning certain “biological drugs” (FDA Law Blog)

US: FDA issues draft MDUFA performance goals and procedures (FDA Law Blog)

US: NPR retraction of story on Apple factories provides insight into the mentality behind attacks on gene patents and agricultural biotechnology (Holman’s Biotech IP Blog) (Holman’s Biotech IP Blog)

US: Supreme Court decision raises interesting questions regarding judicial review of agency action, provides few answers: Sackett v EPA (FDA Law Blog)

US: Precision BioSciences files suit against Cellectis alleging infringement of its patent entitled “methods of cleaving DNA with rationally-designed meganucleases” (Patent Docs)

US: Enzo Life Sciences files patent infringement suits against Hologic, Abbott Laboratories and Becton Dickson over nucleic acid probe products (Patent Docs)

Products

Emamectin benzoate – EU: Plant protection patents and emamectin benzoate – SPCs in Italy / Belgium / Netherlands (The SPC Blog)

Emamectin benzoate – Hungary: Plant SPC from earlier veterinary SPC? Yes, it can be done (The SPC Blog)

Exelon (Rivastigmine) – Spain: Commercial Court of Barcelona: Does a Markush formula with plain bonds comprise both the racemate and its enantiomers? (Kluwer Patent Blog)

Kaletra (Ritonavir and Lopinavir) – Brazil HIV drug patent ruling allows generics, sends pipeline process into doubt (IP Watch)

Nexavar (Sorafenib) – India: More on India-Bayer compulsory license (Patent Baristas)

Nexium (Esomeprazole magnesium) – US: Astrazeneca files patent infringement suits against Mylan, Matrix in New Jersey and Delaware in response to Para IV certification (Patent Docs)

Nuedexta (Dextromethorphan /Quinidine) – US: Avanir files patent infringement suit against Watson Pharmaceuticals in response to Para IV challenge (Patent Docs)

Renagel (Sevelamer) – US: Genzyme files patent infringement suits against Invagen in SD New York and E D New York in response to Para IV certification (Patent Docs)

Seroquel (Quetiapine) – US: D.C. District Court denies preliminary injunction in generic Seroquel litigation; dismisses “premature” lawsuit without prejudice (FDA Law Blog)

Sustiva (Efavirenz) – UK: EWHC (Pat) grants interim injunction restraining Teva from sale of generic Efavirenz pending trial: Bristol-Myers Squibb v Teva (EPLAW) (IPKat)